ArticlemAbs
XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases.
Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 85 citations in OpenAlex.
- Interleukin-1β inhibitors for the management of acute gout flares: a systematic literature review.Arthritis research & therapy · 2023Pooled it
- Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders.Frontiers in immunology · 2022Pooled it
- The right place of interleukin-1 inhibitors in the treatment of Behçet's syndrome: a systematic review.Rheumatology international · 2019Pooled it
- Streamlined stable CHO cell line development using droplet microfluidics with image-based monoclonality assessment.Bioprocess and biosystems engineering · 2026Article
- Integrative Computational Prediction Strategy for Antibody-Antigen Binding: A Case Study on Interleukin-1 Beta.Journal of chemical information and modeling · 2026Article
- Targeting angiopoietin-like protein 3 and interleukin-1β alleviated liver and kidney injury through attenuation of lipotoxicity and regulation of glycolipid metabolism in db/db mice.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Discovery and Phase 1 study of a novel monoclonal antibody against human IL-1β for the treatment of IL-1β-mediated diseases.Clinical and experimental immunology · 2025Article
- CytoSIP: an annotated structural atlas for interactions involving cytokines or cytokine receptors.Communications biology · 2024Article
- Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction.Scientific reports · 2023Article
- The role of inflammation in autoimmune disease: a therapeutic target.Frontiers in immunology · 2023Review
- Analytical Method for Experimental Validation of Computer-Designed Antibody.Methods in molecular biology (Clifton, N.J.) · 2023Article
- The Role of Skin Immune System in Acne.Journal of clinical medicine · 2022Review
- Higher Affinity Antibodies Bind With Lower Hydration and Flexibility in Large Scale Simulations.Frontiers in immunology · 2022Article
- IL-1β in atherosclerotic vascular calcification: From bench to bedside.International journal of biological sciences · 2021Review
- Targeted anti-IL-1β platelet microparticles for cardiac detoxing and repair.Science advances · 2020Article
- Targeting the NLRP3 Inflammasome in Severe COVID-19.Frontiers in immunology · 2020Review
- Targeting IL-1β in the Treatment of Atherosclerosis.Frontiers in immunology · 2020Review
- IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives.Frontiers in immunology · 2020Review
- Interleukin-1 Blockade in Polygenic Autoinflammatory Disorders: Where Are We now?Frontiers in pharmacology · 2020Review
- Biologics in Chronic Rhinosinusitis: An Update and Thoughts for Future Directions.American journal of rhinology & allergy · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-1β (IL-1β) is a potent mediator of inflammatory responses and plays a role in the differentiation of a number of lymphoid cells. In several inflammatory and autoimmune diseases, serum levels of IL-1β are elevated and correlate with disease development and severity. The central role of the IL-1 pathway in several diseases has been validated by inhibitors currently in clinical development or approved by the FDA. However, the need to effectively modulate IL-1β-mediated local inflammation with the systemic delivery of an efficacious, safe and convenient drug still exists. To meet these challenges, we developed XOMA 052 (gevokizumab), a potent anti-IL-1β neutralizing antibody that was designed in silico and humanized using Human Engineering™ technology. XOMA 052 has a 300 femtomolar binding affinity for human IL-1β and an in vitro potency in the low picomolar range. XOMA 052 binds to a unique IL-1β epitope where residues critical for binding have been identified. We have previously reported that XOMA 052 is efficacious in vivo in a diet-induced obesity mouse model thought to be driven by low levels of chronic inflammation. We report here that XOMA 052 also reduces acute inflammation in vivo, neutralizing the effect of exogenously administered human IL-1β and blocking peritonitis in a mouse model of acute gout. Based on its high potency, novel mechanism of action, long half-life, and high affinity, XOMA 052 provides a new strategy for the treatment of a number of inflammatory, autoimmune and metabolic diseases in which the role of IL-1β is central to pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.